Health Discovery Corporation Announces Worldwide License Agreement with Pfizer

Health Discovery Corporation ("HDC") (OTCBB: HDVY) announced today
that it has executed a license agreement with Pfizer Inc. (NYSE: PFE).
Under the terms of the agreement, Pfizer may access HDC's pattern
recognition technology for use in its worldwide research and
development activities. The license includes HDC's Support Vector
Machine ("SVM"), Fractal Genomic Modeling ("FGM"), and related methods
for data analysis. Financial terms of this agreement were not
disclosed.

"I believe this licensing agreement represents a significant step
for HDC towards validating the scientific legitimacy and commercial
viability of our patented SVM and FGM technologies," said Stephen D.
Barnhill, M.D., HDC's Chairman and CEO. "This license marks our third
deal in just the past four months and gives us confidence that our
strategic plan is on track."

"In my opinion, HDC's pattern recognition technology can be an
important tool for the discovery of new drug targets such as proteins,
genes, or other molecules that a drug is intended to affect,"
commented Dr. Herbert A. Fritsche, Jr., Professor of Laboratory
Medicine at the University of Texas M.D. Anderson Cancer Center and
Chairman of HDC's Science Board. "Our technology might also be helpful
in possible identification of new biomarkers to assess both efficacy
and toxic responses to new drugs. As medicine becomes increasingly
personalized, discoveries of this nature could facilitate the
development of new treatments for diseases."

Savannah-based Health Discovery Corporation (OTCBB:HDVY) is
uniquely positioned in the field of pattern recognition technology.
Through the application of its patent protected technology, HDC is a
biology-oriented biomarker discovery company providing all aspects of
First-Phase Biomarker Discovery(sm). The Company's SVM and other
pattern recognition tools have significant application potential in
other sizable commercial markets such as radiology, Internet search
and spam, homeland security, financial futures, and other areas where
analysis of large volumes of complex data is required.

This news release contains "forward-looking statements" within the
meaning of Section 27a of the Securities Acts of 1933 and Section 21E
of the Securities Exchange Act of 1934. Although the management team
of HDC believes that the expectations reflected in such
forward-looking statements are reasonable, it can give no assurance
that such expectations will prove correct.